Pulmonary involvement in Fabry disease

被引:64
|
作者
Brown, LK
Miller, A
Bhuptani, A
Sloane, MF
Zimmerman, I
Schilero, G
Eng, CM
Desnick, RJ
机构
[1] MT SINAI MED CTR, DEPT MED, DIV PULM & CRIT CARE MED, NEW YORK, NY 10029 USA
[2] MT SINAI MED CTR, DEPT HUMAN GENET, NEW YORK, NY 10029 USA
关键词
D O I
10.1164/ajrccm.155.3.9116979
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Fabry disease is an X-linked inborn error of metabolism resulting from deficient activity of alpha-galactosidase A. Although several case reports have suggested an association between Fabry disease and airway obstruction, this has not been investigated in a large series of patients. We studied 25 unselected, consecutive, enzymatically diagnosed men referred to a General Clinical Research Center for evaluation. Thirty-six percent complained of dyspnea, and 24% had cough and/or wheezing. Symptoms were similar in smokers and nonsmokers. Nine (36%) had airway obstruction on spirometry; this finding was associated with age greater than or equal to 26 yr (p < 0.05) and dyspnea or wheezing (p < 0.005), but only weakly with smoking (p = 0.062). Five of eight patients responded to bronchodilators, but all 10 methacholine challenges were negative. Chest radiographs revealed normal lung fields in 24 patients and streaky bibasilar densities in one. No pulmonary uptake occurred on Ga-67 citrate scans (18 patients) and In-111-tagged leukocyte scans (16 patients). Specific alpha-galactosidase A mutations were identified in 17 patients; all three patients with frameshift mutations and both subjects with the D264V missense mutation had obstructive impairment. We conclude that airway obstruction commonly occurs in patients with Fabry disease regardless of smoking history, and it increases with age. The presence of obstruction may be associated with certain mutations and most likely results from fixed narrowing of the airways by accumulated glycosphingolipid.
引用
收藏
页码:1004 / 1010
页数:7
相关论文
共 50 条
  • [41] Renal involvement in Anderson-Fabry disease
    Sessa, A
    Meroni, M
    Battini, G
    Righetti, M
    Maglio, A
    Tosoni, A
    Nebuloni, M
    Vago, G
    Giordano, F
    JOURNAL OF NEPHROLOGY, 2003, 16 (02) : 310 - 313
  • [42] Pulmonary disease and exercise tolerance in boys with Fabry disease
    Wilcox, William
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (02) : S39 - S39
  • [43] Pulmonary disease and exercise tolerance in boys with fabry disease
    Wilcox, William
    MOLECULAR GENETICS AND METABOLISM, 2009, 96 (02) : S46 - S46
  • [44] Fabry disease: Kidney involvement and enzyme replacement therapy
    Siamopoulos, KC
    KIDNEY INTERNATIONAL, 2004, 65 (02) : 744 - 753
  • [45] Prevalence of anderson fabry disease (afd) and cardiac involvement
    Gambarin, F. I.
    Favalli, V.
    Serio, A.
    Pasotti, M.
    Cassini, P.
    Marziliano, N.
    Grasso, M.
    Arbustini, E.
    EUROPEAN HEART JOURNAL, 2009, 30 : 1024 - 1024
  • [46] Fabry disease: Clinical and pathologic manifestations in renal involvement
    Lin, C. -Y.
    CLINICAL THERAPEUTICS, 2008, 30 : S56 - S57
  • [47] Multiple endocrine system involvement in patients with Fabry disease
    Faggiano, A
    Pisani, A
    Pivonello, R
    Filippella, M
    Gaccione, M
    Tortora, F
    Santoro, A
    Vallone, G
    Lombardi, G
    Cianciaruso, B
    Colao, A
    ACTA PAEDIATRICA, 2006, 95 : 130 - 131
  • [48] Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease
    Najafian, Behzad
    Glynn, Emily
    Svarstad, Einar
    Tondel, Camilla
    Whitley, Chester
    Mauer, Michael
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S47 - S48
  • [49] Optic nerve involvement in Fabry disease - a pilot study
    Pitz, S.
    Grube-Einwald, K.
    Reinke, J.
    Renieri, G.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 : S60 - S60
  • [50] Echocardiographic features of cardiac involvement in Fabry's disease
    Nakayama, Y
    Tsumura, K
    Yoshimaru, K
    HEART, 2000, 83 (06) : 695 - 695